April 26, 2024

• 

[THE INVESTOR] Celltrion Healthcare’s drugs will face heightened competition, said Hyundai Motor Investment and Securities on April 20, lowering the target price to 120,000 won (US$112.40) from 145,000 won.

As it competes with firms selling original drugs in North America the average selling price of its therapies will decline, said analyst Kang Yang-gu. 

Approval from US Food and Drug Administration for Truxima and Herzuma is on hold and it may be able to roll them out only in the first half of next year, forecast the analyst, adding that its fixed costs will slightly increase.

However, considering the expanding global market share of its flagship products, including Remsima, Inflectra and Truxima, as well as introducing Herzuma in Europe, Kang maintained a “buy” recommendation. 

By Hwang You-mee (glamazon@heraldcorp.com)